LungLife AI, Inc.

LSE LLAI.L

LungLife AI, Inc. Market Capitalization on January 14, 2025: USD 2.90 M

LungLife AI, Inc. Market Capitalization is USD 2.90 M on January 14, 2025, a -85.91% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

LungLife AI, Inc. 52-week high Market Capitalization is USD 20.59 M on January 15, 2024, which is 609.72% above the current Market Capitalization.
LungLife AI, Inc. 52-week low Market Capitalization is USD 2.85 M on January 02, 2025, which is -1.90% below the current Market Capitalization.
LungLife AI, Inc. average Market Capitalization for the last 52 weeks is USD 7.46 M.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

LSE: LLAI.L

LungLife AI, Inc.

CEO	Dr. Paul Pagano Ph.D.
IPO Date	July 8, 2021
Location	United States
Headquarters	2545 West Hillcrest Drive
Employees	8
Sector	Technology
Industries Artificial Intelligence (AI) Biotechnology

Description

LungLife AI, Inc., a cancer diagnostics company, develops clinical diagnostic solutions for lung cancer with artificial intelligence (AI) technology. It engages in developing LungLB, an AI enhanced, blood-based test to utilize machine learning to identify and count CTCs with reducing operator hands-on time and increasing test performance. The company was formerly known as Cynvenio Biosystems, Inc. and changed its name to LungLife AI, Inc. in May 2019. The company is based in Thousand Oaks, California.

Key trends

Past 5 years